Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

Simple item page
dc.contributor.authorYildirim, HC
dc.contributor.authorMutlu, E
dc.contributor.authorChalabiyev, E
dc.contributor.authorÖzen, M
dc.contributor.authorKeskinkiliç, M
dc.contributor.authorÖn, S
dc.contributor.authorÇelebi, A
dc.contributor.authorDursun, B
dc.contributor.authorAcar, O
dc.contributor.authorKahraman, S
dc.contributor.authorAykan, MB
dc.contributor.authorKaman, O
dc.contributor.authorDogan, A
dc.contributor.authorErdogan, AP
dc.contributor.authorCelayir, OM
dc.contributor.authorGünenç, D
dc.contributor.authorGüven, DC
dc.contributor.authorBayoglu, IV
dc.contributor.authorYavuzsen, T
dc.contributor.authorHacibekiroglu, I
dc.contributor.authorInanç, M
dc.contributor.authorKiliçkap, S
dc.contributor.authorYalçin, S
dc.contributor.authorAksoy, S
dc.date.accessioned2025-04-10T10:37:22Z
dc.date.available2025-04-10T10:37:22Z
dc.description.abstractBackground: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4-6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4-6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04-25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4-6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4-6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4-6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer.
dc.identifier.e-issn1532-3080
dc.identifier.issn0960-9776
dc.identifier.urihttp://hdl.handle.net/20.500.14701/42980
dc.language.isoEnglish
dc.titleClinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu